The biotech’s lead asset, furmonertinib, is being developed for non-small cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitor received approval in China in 2021 to treat locally ...

ArriVent is using this money to support its cancer-focused pipeline, specifically to fund the New Drug Application of its lead asset furmonertinib, an oral and brain-penetrant EGFR inhibitor, for ...

The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...

Earth's inner core may actually have two distinct layers. (alexlmx/Canva Pro) "We found evidence that may indicate a change in the structure of iron, which suggests perhaps two separate cooling events ...